71 related articles for article (PubMed ID: 10918951)
1. Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data.
Marzo A; Monti NC; Tettamanti RA; Crivelli F; Dal Bo L; Mazzucchelli P; Meoli A; Pezzuto D; Corsico A
Arzneimittelforschung; 2000 Jun; 50(6):559-63. PubMed ID: 10918951
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
3. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers.
Petzold U; Kremer HJ; Nguyen DT; Munzel U; Dietrich H; Maus J
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):309-19. PubMed ID: 18598160
[TBL] [Abstract][Full Text] [Related]
5. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
[TBL] [Abstract][Full Text] [Related]
6. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer.
Randell J; Saarinen A; Walamies M; Vahteristo M; Silvasti M; Lähelmä S
Respir Med; 2005 Dec; 99(12):1485-93. PubMed ID: 16226024
[TBL] [Abstract][Full Text] [Related]
7. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.
Carlsen KH; Hem E; Stensrud T; Held T; Herland K; Mowinckel P
Respir Med; 2001 Jul; 95(7):571-6. PubMed ID: 11453313
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
9. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of inhaled formoterol in reversing bronchoconstriction.
Rubin AS; Perin C; Pelegrin L; Fernandes JC; da Silva LC
J Bras Pneumol; 2006; 32(3):202-6. PubMed ID: 17273608
[TBL] [Abstract][Full Text] [Related]
11. The use of inhaled formoterol in the treatment of asthma.
Berger WE
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
[TBL] [Abstract][Full Text] [Related]
12. The effect of formoterol inhalation on endurance performance in hypobaric conditions.
Riiser A; Tjørhom A; Carlsen KH
Med Sci Sports Exerc; 2006 Dec; 38(12):2132-7. PubMed ID: 17146320
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing.
van den Berg BT; Braat MC; van Boxtel CJ
Eur J Clin Pharmacol; 1998 Aug; 54(6):463-8. PubMed ID: 9776436
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
[TBL] [Abstract][Full Text] [Related]
15. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
16. On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches.
Soulele K; Macheras P; Karalis V
Pulm Pharmacol Ther; 2018 Feb; 48():168-178. PubMed ID: 29223508
[TBL] [Abstract][Full Text] [Related]
17. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
Lötvall J; Ankerst J
Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
19. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
